- Q1 2024 IMCD NV Earnings Call TranscriptApr 26, 2024$75.65 (-5.47%)Earnings
- Q3 2023 IMCD NV Earnings Call TranscriptNov 10, 2023$68.04 (-0.63%)Earnings
- Q2 2023 IMCD NV Earnings Call TranscriptAug 04, 2023$70.1 (-2.00%)Earnings
- Q1 2023 IMCD NV Earnings Call TranscriptApr 26, 2023$76.8 (-3.58%)Earnings
- Q4 2022 IMCD NV Earnings Call TranscriptFeb 24, 2023$76.34 (-3.71%)Earnings
- Q3 2022 IMCD NV Earnings Call TranscriptNov 10, 2022$74.5 (+12.22%)Earnings
- Q2 2022 IMCD NV Earnings Call TranscriptAug 04, 2022$79.65Earnings
- Q1 2022 IMCD NV Earnings Call TranscriptApr 29, 2022$80.74 (-28.53%)Earnings
- Q4 2021 IMCD NV Earnings Call TranscriptFeb 25, 2022$112.97Earnings
- Q3 2021 IMCD NV Earnings Call TranscriptNov 09, 2021$112.97Earnings
- Q2 2021 IMCD NV Earnings Call TranscriptAug 04, 2021$44.85Earnings
- Q1 2021 IMCD NV Earnings Call TranscriptApr 29, 2021$44.85Earnings
- Full Year 2020 IMCD NV Earnings Call TranscriptFeb 26, 2021$44.85Earnings
- Nine Months 2020 IMCD NV Earnings Call TranscriptNov 11, 2020$44.85Earnings
- IMCD N.V., Signet Excipients Private Limited - M&A Call TranscriptSep 15, 2020
- Half Year 2020 IMCD NV Earnings Call TranscriptAug 18, 2020$44.85Earnings
- Q1 2020 IMCD NV Trading Update Call TranscriptApr 20, 2020
- Full Year 2019 IMCD NV Earnings Call TranscriptFeb 27, 2020$44.85Earnings
- Nine Months 2019 IMCD NV Earnings Call TranscriptNov 12, 2019$44.85Earnings
- Half Year 2019 IMCD NV Earnings Call TranscriptAug 16, 2019$44.85Earnings
- Q1 2019 IMCD NV Earnings Call TranscriptMay 08, 2019Earnings
- Full Year 2018 IMCD NV Earnings Call TranscriptMar 01, 2019Earnings
Q1 2023 IMCD NV Earnings Call Transcript
Please go ahead.
Good morning, everyone. As usual, I'm here with Hans Kooijmans and we're happy to take your questions in a moment.
My name is Pieter Slikke. We started 2023 with a strong first quarter with an EBITA growth of 6% and even adjusted for ForEx 8%. Certainly, when you realized that we grew Q1 2022 with 59%, we were able to hold revenue more or less at the same level as quarter 1, 2023, and we're able to increase our margin. The business segments in Life Science performed quite well.
In the industrial segments, we saw effects of destocking and slowing down of demand. We completed 2 acquisitions in Q1, 1 in the U.K. and 1 in China. Sunrise in China will give us a strong position in the beauty and personal care market in that country. We closed a small bolt-on acquisition in Sweden last week, signed 2 deals in South Africa and India, and we expect to do more acquisitions in the course of this year. So we have proven resilience throughout our history. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)